初诊乳腺癌患者腹部增强分期CT的诊断检出率
回顾性分析2056例初诊乳腺癌患者,腹部增强分期CT检出乳腺癌肝转移的总体诊断检出率为1.1%(22/2056)。III期患者检出率3.9%(18/467)显著高于I期0%(0/412)或II期0.4%(4/1158),HER2富集型2.9%(16/560)显著高于Luminal型0.4%(4/1090)或三阴性0.5%(2/406),p均<.001。结论认为对所有初诊乳腺癌患者行腹部分期CT可能不必要,但在III期或HER2富集型患者中可能具有临床价值。
要点
- 初诊乳腺癌腹部增强分期CT检出肝转移的总体诊断检出率仅1.1%(22/2056)。
- III期检出率3.9%(18/467),显著高于I期0%和II期0.4%(p<.001)。
- HER2富集型检出率2.9%(16/560),显著高于Luminal型0.4%和三阴性0.5%(p<.001)。
核心结论
- 初诊乳腺癌患者腹部分期CT检出肝转移的总体诊断检出率低(1.1%),对所有患者可能不必要,但在III期或HER2富集型患者中可能具有临床价值。
研究设计与样本
- 回顾性分析2019年1月至2020年12月间初诊乳腺癌并接受腹部CT作为初始分期检查的患者共2056例(平均年龄51±11岁)。
诊断标准与关键数值
- 总体诊断检出率1.1%(22/2056)。
- III期诊断检出率3.9%(18/467) vs I期0%(0/412)或II期0.4%(4/1158),p<.001。
- HER2富集型诊断检出率2.9%(16/560) vs Luminal型0.4%(4/1090)或三阴性0.5%(2/406),p<.001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To estimate the diagnostic yield (DY) of abdominal staging CT for detecting breast cancer liver metastasis (BCLM) in patients with initially diagnosed breast cancer and to determine the indications for abdominal staging CT.
METHODS: Patients with newly diagnosed breast cancer who underwent abdominal CT as an initial staging work-up between January 2019 and December 2020 were retrospectively analyzed. DY was calculated and analyzed according to patient age, type of treatments, histologic type, histologic grade, lymphovascular invasion, Ki-67 status, hormone receptor status, subtype, and the American Joint Committee on Cancer anatomical staging.
RESULTS: A total of 2056 patients (mean age, 51 ± 11 years) were included. The DY of abdominal staging CT for detecting BCLM was 1.1 % (22 of 2056). DY was significantly higher in stage III than in stage I or II cancers (3.9 % [18 of 467] vs. 0 % [0 of 412] or 0.4 % [4 of 1158], respectively, p < .001), and in human epidermal growth factor receptor-2 (HER2)-enriched cancers than in luminal or triple negative cancers (2.9 % [16 of 560] vs. 0.4 % [4 of 1090] or 0.5 % [2 of 406], respectively, p < .001).
CONCLUSIONS: The DY of abdominal staging CT for detecting BCLM was low among all patients with initially diagnosed breast cancer. However, although abdominal staging CT for detecting BCLM is probably unnecessary in all patients, it can be clinically useful in patients with stage III or human epidermal growth factor receptor-2-enriched breast cancers.
引用
- Jeong B, Lee YW, Lee SB, et al. Diagnostic yield of contrast-enhanced abdominal staging CT in patients with initially diagnosed breast cancer. Eur J Radiol. 2024. PMID: 38241854. doi:10.1016/j.ejrad.2024.111295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。